

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ALVOGEN PINE BROOK LLC

Petitioner,

v.

CELGENE CORP.

Patent Owner

Case No. UNASSIGNED

Patent 7,968,569

PETITION FOR *INTER PARTES* REVIEW OF CLAIMS 1-15
OF U.S. PATENT NO. 7,968,569

TABLE OF CONTENTS

| | Page |
|--|-------------|
| I. INTRODUCTION | 1 |
| A. Preliminary Statement | 1 |
| B. Summary of Unpatentability Grounds..... | 2 |
| II. MANDATORY NOTICES, STANDING, AND FEES..... | 2 |
| A. Mandatory Notices..... | 2 |
| B. Certification of Grounds for Standing..... | 3 |
| C. Fees | 4 |
| III. OVERVIEW OF THE '569 PATENT | 4 |
| A. The Claims of the '569 Patent | 4 |
| B. The Effective Filing Date of the '569 Patent Can Be No Earlier than November 6, 2002 | 4 |
| IV. CLAIM CONSTRUCTION | 7 |
| V. LEVEL OF ORDINARY SKILL IN THE ART | 7 |
| VI. SUMMARY OF THE PRIOR ART | 8 |
| A. Thalidomide and Thalidomide Analogs (IMiDs)..... | 8 |
| 1. Muller | 8 |
| 2. Corral I and II | 10 |
| 3. The '230 Patent | 11 |
| B. Multiple Myeloma and Thalidomide..... | 12 |
| 1. Palumbo..... | 14 |
| C. Multiple Myeloma and IMiDs..... | 15 |

Petition for *Inter Partes* Review of U.S. Patent No. 7,968,569

| | |
|---|----|
| 1. Hideshima..... | 16 |
| 2. May Press Release..... | 18 |
| D. A POSA Would Understand that “Revimid” is Lenalidomide | 20 |
| 1. August Press Release | 21 |
| 2. Orphan Drug Designation | 23 |
| E. Drug Cycling in Cancer Treatments..... | 25 |
| VII. THERE IS A REASONABLE LIKELIHOOD THAT THE CHALLENGED CLAIMS ARE UNPATENTABLE | 29 |
| A. Ground 1: The Combination of Palumbo, the May Press Release, and the August Press Release Renders Claims 1-15 Obvious | 29 |
| 1. A POSA would have been motivated to combine Palumbo, the May Press Release, and the August Press Release | 29 |
| 2. Claims 1 and 13..... | 30 |
| 3. Claims 2 and 4..... | 37 |
| 4. Claim 3 | 38 |
| 5. Claims 5, 6, and 15..... | 38 |
| 6. Claims 7–12..... | 39 |
| 7. Claim 14 | 40 |
| B. Ground 2: Palumbo, Hideshima, and the ’230 Patent | 41 |
| 1. A POSA would have been motivated to combine Palumbo, Hideshima, and the ’230 patent..... | 41 |
| 2. Claims 1 and 13..... | 43 |
| 3. Claims 2 and 4..... | 51 |
| 4. Claim 3 | 52 |
| 5. Claims 5, 6, and 15..... | 53 |

Petition for *Inter Partes* Review of U.S. Patent No. 7,968,569

| | |
|--|----|
| 6. Claims 7–12..... | 54 |
| 7. Claim 14 | 55 |
| C. There Are No Secondary Considerations to Overcome Obviousness..... | 56 |
| 1. There Are No Unexpected Results..... | 57 |
| 2. Revlimid’s Alleged Commercial Success Does Not Support the ’569 patent | 61 |
| VIII. CONCLUSION..... | 63 |

LIST OF EXHIBITS

| Exhibit No. | Document |
|--------------------|---|
| Ex. 1001 | U.S. Patent No. 7,968,569 (“the ’569 patent”) |
| Ex. 1002 | Prosecution History excerpts for U.S. Patent No. 7,968,569 |
| Ex. 1003 | Expert Declaration of Dr. Guido Tricot |
| Ex. 1004 | Sampaio et al., “Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes,” <i>J. Exp. Med.</i> , 173(3): 699-703 (1991). (“Sampaio”) |
| Ex. 1005 | Tramontana et al., “Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis,” <i>Molecular Medicine</i> , 1:384-397 (1995). (“Tramontana”) |
| Ex. 1006 | Singhal et al., “Antitumor Activity of Thalidomide in Refractory Multiple Myeloma,” <i>N. Engl. J. Med.</i> , 341:1565-1571 (1999) (“Singhal”) |
| Ex. 1007 | Durie & Stepan, “Efficacy of Low Dose Thalidomide in Multiple Myeloma,” <i>Electronic Journal of Oncology</i> , 1:1-8 (2000). (“Durie”) |
| Ex. 1008 | Muller et al., “Amino-substituted Thalidomide Analogues: Potent Inhibitors of TNF- α Productions,” <i>Bioorganic & Medicinal Chemistry Letters</i> , 9:1625-1630 (1999). (“Muller”) |
| Ex. 1009 | Corral et al., “Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That are Potent Inhibitors of TNF- α ,” <i>J. Immunol.</i> , 163: 380-386 (1999). (“Corral I”) |
| Ex. 1010 | Corral & Kaplan, “Immunomodulation by thalidomide and thalidomide analogues,” <i>Ann. Rheum. Dis.</i> , 58: I107-I113 (1999). (“Corral II”) |
| Ex. 1011 | Rajkumar & Kyle, “Thalidomide in the Treatment of Plasma Cell Malignancies,” <i>J. of Clinical Oncology</i> , 19(16):3593-3595 (Aug. 2001). (“Rajkumar 2001”) |
| Ex. 1012 | Celgene Corp., “Positive Interim Results Presented at the VIIIth International Myeloma Workshop on Celgene Corporation's Lead IMiD(TM) (REVIMID(TM)); Lead Investigators from Dana-Farber Cancer Institute and the Arkansas Cancer Research Center Reported on REVIMID's Activity and Safety Profile,” May 8, 2001. (“May Press Release”) |
| Ex. 1013 | Celgene Corp., “Celgene Corporation Awarded Additional Patent |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.